340 related articles for article (PubMed ID: 25814083)
21. Successful management of chronic myeloid leukaemia with leucapheresis during a twin pregnancy.
Klaasen R; de Jong P; Wijermans PW
Neth J Med; 2007 Apr; 65(4):147-9. PubMed ID: 17452764
[TBL] [Abstract][Full Text] [Related]
22. Optimising chronic myeloid leukaemia therapy in the face of resistance to tyrosine kinase inhibitors--a synthesis of clinical and laboratory data.
Irvine DA; Heaney NB; Holyoake TL
Blood Rev; 2010 Jan; 24(1):1-9. PubMed ID: 20005615
[TBL] [Abstract][Full Text] [Related]
23. Pregnancy among patients with chronic myeloid leukemia treated with imatinib.
Ault P; Kantarjian H; O'Brien S; Faderl S; Beran M; Rios MB; Koller C; Giles F; Keating M; Talpaz M; Cortes J
J Clin Oncol; 2006 Mar; 24(7):1204-8. PubMed ID: 16446320
[TBL] [Abstract][Full Text] [Related]
24. Outcome of pregnancy in chronic myeloid leukaemia patients treated with tyrosine kinase inhibitors: short report from a single centre.
Alizadeh H; Jaafar H; Rajnics P; Khan MI; Kajtár B
Leuk Res; 2015 Jan; 39(1):47-51. PubMed ID: 25455655
[TBL] [Abstract][Full Text] [Related]
25. [Therapeutic strategy for chronic myeloid leukemia: possibilities and prospects].
Turkina AG; Chelysheva EIu
Ter Arkh; 2013; 85(7):4-9. PubMed ID: 24137941
[TBL] [Abstract][Full Text] [Related]
26. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
An X; Tiwari AK; Sun Y; Ding PR; Ashby CR; Chen ZS
Leuk Res; 2010 Oct; 34(10):1255-68. PubMed ID: 20537386
[TBL] [Abstract][Full Text] [Related]
27. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
Rousselot P; Charbonnier A; Cony-Makhoul P; Agape P; Nicolini FE; Varet B; Gardembas M; Etienne G; Réa D; Roy L; Escoffre-Barbe M; Guerci-Bresler A; Tulliez M; Prost S; Spentchian M; Cayuela JM; Reiffers J; Chomel JC; Turhan A; Guilhot J; Guilhot F; Mahon FX
J Clin Oncol; 2014 Feb; 32(5):424-30. PubMed ID: 24323036
[TBL] [Abstract][Full Text] [Related]
28. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
29. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia.
Dusetzina SB; Winn AN; Abel GA; Huskamp HA; Keating NL
J Clin Oncol; 2014 Feb; 32(4):306-11. PubMed ID: 24366936
[TBL] [Abstract][Full Text] [Related]
30. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Wongboonma W; Thongnoppakhun W; Auewarakul CU
Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
[TBL] [Abstract][Full Text] [Related]
31. Response-related predictors of survival in CML.
Hanfstein B; Müller MC; Hochhaus A
Ann Hematol; 2015 Apr; 94 Suppl 2():S227-39. PubMed ID: 25814089
[TBL] [Abstract][Full Text] [Related]
32. Controversies in the treatment of CML in children and adolescents: TKIs versus BMT?
Suttorp M; Yaniv I; Schultz KR
Biol Blood Marrow Transplant; 2011 Jan; 17(1 Suppl):S115-22. PubMed ID: 21195300
[TBL] [Abstract][Full Text] [Related]
33. Fertility considerations in targeted biologic therapy with tyrosine kinase inhibitors: a review.
Rambhatla A; Strug MR; De Paredes JG; Cordoba Munoz MI; Thakur M
J Assist Reprod Genet; 2021 Aug; 38(8):1897-1908. PubMed ID: 33826052
[TBL] [Abstract][Full Text] [Related]
34. Allogeneic transplantation for CML in the TKI era: striking the right balance.
Innes AJ; Milojkovic D; Apperley JF
Nat Rev Clin Oncol; 2016 Feb; 13(2):79-91. PubMed ID: 26573423
[TBL] [Abstract][Full Text] [Related]
35. Management of chronic myeloid leukemia in blast crisis.
Saußele S; Silver RT
Ann Hematol; 2015 Apr; 94 Suppl 2():S159-65. PubMed ID: 25814082
[TBL] [Abstract][Full Text] [Related]
36. Overview of second-generation tyrosine kinase inhibitors for patients with imatinib-resistant chronic myelogenous leukemia.
Ault P
Clin J Oncol Nurs; 2007 Feb; 11(1):125-9. PubMed ID: 17441403
[TBL] [Abstract][Full Text] [Related]
37. How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy.
Rea D; Mahon FX
Br J Haematol; 2018 Jan; 180(1):24-32. PubMed ID: 29048128
[TBL] [Abstract][Full Text] [Related]
38. Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Breccia M; Colafigli G; Molica M; Alimena G
Expert Opin Drug Saf; 2016; 15(4):525-33. PubMed ID: 26799331
[TBL] [Abstract][Full Text] [Related]
39. Renal failure associated with tyrosine kinase inhibitors--case report and review of the literature.
Gafter-Gvili A; Ram R; Gafter U; Shpilberg O; Raanani P
Leuk Res; 2010 Jan; 34(1):123-7. PubMed ID: 19640584
[TBL] [Abstract][Full Text] [Related]
40. Second-line therapy for patients with chronic myeloid leukemia resistant to first-line imatinib.
Lau A; Seiter K
Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):186-96. PubMed ID: 24456839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
